Tim Schlidt next to the Hone In logo
Tim Schlidt: How Ketamine, Psilocybin, MDMA Rewire the Brain for Mental Health
A psychedelic VC-fund is revolutionizing PTSD and trauma care for hard-to-treat cases.

Tim Schlidt is the co-founder of psychedelic-focused VC fund Palo Santo. He is one of the leading voices pushing for the development of psychedelic-backed mental health therapies and has deployed over $25 million into 20 companies. Schlidt is also pushing for the FDA approval of psychedelic-assisted therapies to make them more accessible, affordable, and safe for patients suffering from treatment-resistant depression. 

In this episode of Hone In, host Saad Alam sat down with him to talk about what goes down during a therapeutic trip, ongoing clinical trials for psychedelics including ketamine, MDMA, and psilocybin, and the growing acceptance of psychedelics in mental health care.

This conversation is an absolute game-changer. It covers both scientific inquiry and personal experiences, offering you a comprehensive understanding of the profound potential of therapeutic psychedelics. 

Listen on:


  • How psychedelics literally rewire your brain by promoting neuroplasticity
  • The anti-inflammatory and longevity benefits of psychedelics
  • How MDMA and psilocybin are being used to treat PTSD and treatment-resistant depression
  • How Tim’s own experience with severe depression led him to invest in companies researching psychedelics
  • The mental health benefits of “ego death”
Tim Schildt Quote | Hone In


  • The difference between a psychedelic microdose and a macrodose
  • Why psychedelics could yield better results than SSRIs
  • When to expect FDA approval of psychedelic therapies
  • How much psychedelic-assisted therapy costs
  • And more
A photo of Tim Schlidt